Nasdaq Approves Listing of Canary’s Staked Injective ETF
AI summary
Nasdaq has approved the listing of Canary's staked Injective ETF, which would stake at least 90% of its INJ holdings and charge a 1.10% annual sponsor fee. The approval brings a yield-bearing altcoin ETF closer to trading, expanding institutional access to Injective. Traders would watch for final regulatory clearance and potential INJ demand from the fund's staking requirements.
